Deltec Asset Management LLC Sells 3,000 Shares of Illumina, Inc. (NASDAQ:ILMN)

Deltec Asset Management LLC lessened its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 40.0% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 4,500 shares of the life sciences company’s stock after selling 3,000 shares during the quarter. Deltec Asset Management LLC’s holdings in Illumina were worth $601,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Empowered Funds LLC boosted its holdings in shares of Illumina by 1.7% during the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC raised its position in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock valued at $376,000 after purchasing an additional 83 shares during the last quarter. Integrated Advisors Network LLC boosted its stake in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock valued at $585,000 after purchasing an additional 90 shares in the last quarter. Moors & Cabot Inc. grew its holdings in shares of Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after purchasing an additional 95 shares during the last quarter. Finally, Spire Wealth Management increased its stake in shares of Illumina by 26.0% in the fourth quarter. Spire Wealth Management now owns 470 shares of the life sciences company’s stock valued at $63,000 after buying an additional 97 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Illumina Trading Down 5.3 %

Shares of Illumina stock opened at $124.20 on Wednesday. The stock has a market capitalization of $19.70 billion, a PE ratio of -12.47 and a beta of 1.10. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a 50 day moving average price of $138.19 and a two-hundred day moving average price of $135.50. The company has a debt-to-equity ratio of 0.94, a quick ratio of 1.85 and a current ratio of 2.43.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 EPS. Illumina’s quarterly revenue was down 3.5% on a year-over-year basis. As a group, equities analysts anticipate that Illumina, Inc. will post 4.13 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. Hsbc Global Res upgraded shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 target price on the stock in a research report on Thursday, October 17th. Stephens lifted their price target on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, November 12th. Piper Sandler reduced their price objective on shares of Illumina from $195.00 to $185.00 and set an “overweight” rating on the stock in a research note on Monday, November 11th. Canaccord Genuity Group raised their target price on Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research report on Tuesday, November 5th. Finally, Barclays reduced their price target on Illumina from $145.00 to $130.00 and set an “equal weight” rating on the stock in a research report on Monday. Eight research analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and a consensus target price of $164.84.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.